<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976729</url>
  </required_header>
  <id_info>
    <org_study_id>SNOXE36C001</org_study_id>
    <nct_id>NCT00976729</nct_id>
  </id_info>
  <brief_title>NOX-E36 First-in-Human (FIH) Study</brief_title>
  <official_title>NOX-E36 - A Phase I, Double-Blind, Placebo Controlled, Single Intravenous and Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NOXXON Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NOXXON Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is the first time NOX-E36 will be administered to man. The principal aim of this study
      is to obtain safety and tolerability data when NOX-E36 is administered by single intravenous
      (IV) and subcutaneous (SC) doses to healthy male and female subjects. This information,
      together with the pharmacokinetic and pharmacodynamic data, will help establish the doses,
      dosage regimen and route of administration suitable for multiple dose administration to
      healthy volunteers, followed by the studies in the patient population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of NOX-E36 by means of adverse events, vital signs, laboratory parameters, 12-lead ECG and immunogenicity assessment</measure>
    <time_frame>throughout the entire study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters in plasma and urine</measure>
    <time_frame>throughout the entire study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic profile</measure>
    <time_frame>throughout the entire study</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Chronic Inflammatory Diseases</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Placebo i.v.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.03 mg/kg i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.09 mg/kg i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25 mg/kg i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg/kg i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1.0 mg/kg i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0 mg/kg i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo s.c.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25 mg/kg s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg/kg s.c.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX-E36</intervention_name>
    <description>single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg</description>
    <arm_group_label>0.03 mg/kg i.v.</arm_group_label>
    <arm_group_label>0.09 mg/kg i.v.</arm_group_label>
    <arm_group_label>0.25 mg/kg i.v.</arm_group_label>
    <arm_group_label>0.5 mg/kg i.v.</arm_group_label>
    <arm_group_label>1.0 mg/kg i.v.</arm_group_label>
    <arm_group_label>2.0 mg/kg i.v.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX-E36</intervention_name>
    <description>single SC doses, at safe and tolerable dose level</description>
    <arm_group_label>0.25 mg/kg s.c.</arm_group_label>
    <arm_group_label>0.5 mg/kg s.c.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo i.v.</arm_group_label>
    <arm_group_label>Placebo s.c.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects

          -  Body mass index (BMI) between 19.0 and 29.0 kg/m2 inclusive

          -  Body weight between 50 and 100 kg inclusive

          -  Creatinine clearance of greater than 80 mL/min

        Exclusion Criteria:

          -  Male and female subjects who are not or whose partners are not willing to use
             appropriate contraception methods

          -  Intake of any prescribed systemic or topical medication within 14 days prior to dosing

          -  Intake of any non-prescribed systemic or topical medication (including herbal
             remedies) within 7 days prior to dosing (with the exception of vitamin/mineral
             supplements)

          -  Supine blood pressure and supine pulse rate higher than 140/90 mmHg and 100 beats per
             minute (bpm), respectively, or lower than 90/50 mmHg and 40 bpm, respectively, as
             confirmed by a repeat assessment

          -  History of any clinically significant neurological, dermatological, gastrointestinal,
             renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine,
             haematological or other major disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grit Landgraf, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Noxxon AG</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2009</study_first_submitted>
  <study_first_submitted_qc>September 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2009</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>monocyte chemoattractant protein-1 (MCP-1)</keyword>
  <keyword>L-oligonucleotide aptamer</keyword>
  <keyword>Spiegelmer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

